Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer

被引:15
|
作者
Lim, Ilhan [2 ]
Kim, Seok-ki [1 ]
Hwang, Seung-sik [3 ]
Kim, Sun Wook [4 ]
Chung, Ki Wook [5 ]
Kang, Han Sung [5 ]
Lee, Eun Sook [5 ]
机构
[1] Natl Canc Ctr, Res Inst & Hosp, Dept Nucl Med, Goyang 411769, Gyeonggi, South Korea
[2] Korea Canc Ctr Hosp, Dept Nucl Med, Seoul, South Korea
[3] Natl Canc Ctr, Res Inst Natl Canc Control & Evaluat, Goyang 411769, Gyeonggi, South Korea
[4] Natl Canc Ctr, Dept Internal Med, Res Inst & Hosp, Goyang 411769, Gyeonggi, South Korea
[5] Natl Canc Ctr, Dept Surg, Res Inst & Hosp, Goyang 411769, Gyeonggi, South Korea
基金
新加坡国家研究基金会;
关键词
Thyroid; Differentiated thyroid cancer; Radioiodine ablation; Thyroglobulin; Whole body scan; REMNANT ABLATION; CERVICAL UPTAKE; I-131; CARCINOMA; PAPILLARY; MANAGEMENT; EFFICACY; TISSUE; LEVEL; TIME;
D O I
10.1007/s12149-012-0640-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
To investigate predictors for successful ablation and disease-free status after high-dose radioiodine therapy in patients with differentiated thyroid cancer. We enrolled 173 consecutive patients with differentiated thyroid cancer between November 2001 and December 2004 retrospectively (female 145, 46 +/- A 12 years). All patients underwent total thyroidectomy and I-131 ablative therapy (IAT) (3.7-5.4 GBq). The success or failure of ablation was assessed 6-9 months after the IAT with reference to undetectable thyroglobulin (Tg) and negative I-131 whole body scan (WBS). Afterward, the decision for disease-free status was evaluated using Tg and WBS (follow-up period after 1st IAT 7-81 months, median 43 months, criteria of disease-free: less than 10 ng/ml TSH-stimulated Tg or less than 2 ng/ml TSH-unstimulated Tg and/or negative WBS). Clinical and tumoral factors such as sex, age, pathologic type, the size of tumor, quantified cervical uptake in WBS1, pattern in WBS1, ablative therapy dose, AJCC stage, lymph node (LN) stage, Tg just before IAT (Tg1), and ablation status were assessed using logistic regression analyses. There were 93 successful ablations (54 %). Significant predictors for the ablation failure were Tg1 (OR = 8.42; 95 % CI = 2.76-25.69; p < 0.0001), LN metastasis (OR = 3.05; 95 % CI = 1.11-8.37; p = 0.031), and quantified cervical uptake in WBS1 (OR = 4.95; 95 % CI = 1.07-22.88; p = 0.041). One hundred fifty-five patients were determined as disease-free after follow-up. All the eighteen patients with persistent disease were identified as ablation failure after first IAT. Significant predictors for the disease-free status were Tg1 (OR = 0.98; 95 % CI = 0.97-0.99; p = 0.028), tumor size (OR = 0.53; 95 % CI = 0.28-0.96; p = 0.044), and quantified cervical uptake in WBS1 (OR = 0.87; 95 % CI = 0.76-0.98; p = 0.024). The thyroglobulin and quantified cervical uptake in whole body scan are significant predictors for the successful ablation and disease-free status after follow-up.
引用
收藏
页码:777 / 786
页数:10
相关论文
共 50 条
  • [31] Evaluation of radioiodine therapy in differentiated thyroid cancer (DTC) in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels:: A comparison study with thallium scan
    Zakani, A.
    Saghari, M.
    Eftekhari, M.
    Fard-Esfahani, A.
    Asadi, M.
    Fallahi, B.
    Beiki, D.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S358 - S358
  • [32] Low correlation between serum thyroglobulin and 131I radioiodine whole body scintigraphy: implication for postoperative disease surveillance in differentiated thyroid cancer
    Thai, Janice N.
    Marchena, Ingrid Rymer De
    Nehru, Vijeyaluxmy Motilal
    Landau, Elliot
    Demissie, Seleshi
    Josemon, Raina
    Peti, Steven
    Brenner, Arnold I.
    [J]. CLINICAL IMAGING, 2022, 87 : 1 - 4
  • [33] Low correlation between serum thyroglobulin and 131I radioiodine whole body scintigraphy: implication for postoperative disease surveillance in differentiated thyroid cancer
    Thai, Janice N.
    De Marchena, Ingrid Rymer
    Nehru, Vijeyaluxmy Motilal
    Landau, Elliot
    Demissie, Seleshi
    Josemon, Raina
    Peti, Steven
    Brenner, Arnold I.
    [J]. Clinical Imaging, 2022, 87 : 1 - 4
  • [34] The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial 131I therapy
    van Dijk, D.
    Plukker, J. T. M.
    van der Horst-Schrivers, A. N. A.
    Jansen, L.
    Brouwers, A. H.
    Muller-Kobold, A.
    Sluiter, W. J.
    Links, T. P.
    [J]. CLINICAL ENDOCRINOLOGY, 2011, 74 (01) : 104 - 110
  • [35] Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups
    Zakani, A.
    Saghari, M.
    Eftekhari, M.
    Fard-Esfahani, A.
    Fallahi, B.
    Esmaili, J.
    Assadi, M.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2011, 15 (10) : 1215 - 1221
  • [36] Undetectable ablation thyroglobulin in patients with differentiate thyroid cancer showing 131I uptake on post-ablation therapy whole-body scan
    Alban, F.
    Guelho, D.
    Costa, G.
    Albuquerque, A.
    Pedroso de Lima, J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S547 - S547
  • [37] Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis
    Huang, Shu-Hua
    Wang, Pei-Wen
    Huang, Yu-Erh
    Chou, Fong-Fu
    Liu, Rue-Tsuan
    Tung, Shih-Chen
    Chen, Jung-Fu
    Kuo, Ming-Chun
    Hsieh, Jing-Rong
    Hsieh, Hsin-Hung
    [J]. THYROID, 2006, 16 (12) : 1273 - 1278
  • [38] Clinical impact of circulating anti-thyroglobulin autoantibodies on the prediction of recurrence in patients with differentiated thyroid cancer after first remnant ablation
    Shen, G.
    Hu, S.
    Kuang, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S729 - S730
  • [39] Is there an added value for whole body scan combined with stimulated thyroglobulin testing for follow-up of differentiated thyroid cancer patients?
    Giveon, Sharon
    Levy, Sigal
    Rotman-Pikielny, Pnina
    Rosenblum, Rachel Chava
    Twito, Orit
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (06) : 663 - 668
  • [40] Thyroglobulin Antibodies as a Prognostic Factor in Papillary Thyroid Carcinoma Patients with Indeterminate Response After Initial Therapy
    Landenberger, Giullia Menuci Chianca
    Salerno, Marianna Lins de Souza
    Golbert, Lenara
    Meyer, Erika Laurini de Souza
    [J]. HORMONE AND METABOLIC RESEARCH, 2021, 53 (02) : 94 - 99